Pharmacology, Toxicology and Pharmaceutical Science
Cross-Sectional Study
100%
Cholinergic Receptor Blocking Agent
39%
Randomized Clinical Trial
28%
Community Pharmacy
28%
Prescription Medication
25%
Adverse Event
20%
Non Prescription Drug
19%
Exposure to Violence
19%
Antifungal Agent
19%
Neurologic Disease
19%
Tablet
19%
Drug Interaction
19%
Infection
19%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
19%
Statin (Protein)
19%
Mycosis
19%
Vancomycin
19%
Apixaban
19%
Hemodialysis
19%
FDA Adverse Event Reporting System
19%
Atrial Fibrillation
19%
Multiple Myeloma
19%
Therapeutic Drug Monitoring
19%
Low Density Lipoprotein Cholesterol
14%
Systemic Mycosis
12%
Diabetes Mellitus
11%
Prevalence
9%
Beers Criteria
9%
Cross Sectional Study
9%
Hospital Mortality
9%
Lung Disease
9%
Diseases
9%
Virus Transmission
9%
COVID-19 Vaccine
9%
Acute Kidney Failure
9%
Hospital Pharmacy
9%
Atorvastatin
8%
Dyslipidemia
8%
Rosuvastatin
6%
Withdrawal Syndrome
6%
Cohort Study
5%
Ixazomib
5%
Nursing and Health Professions
Cross-Sectional Study
86%
Cholinergic Receptor Blocking Agent
21%
Booster Dose
19%
Multiple Linear Regression Analysis
19%
Non Prescription Drug
19%
Household
19%
Health Belief Model
19%
University Student
19%
Adverse Drug Reaction
19%
Drug Use
19%
Potentially Inappropriate Medication
19%
COVID-19
19%
Treatment Duration
19%
Primary Medical Care
19%
Therapeutic Drug Monitoring
19%
Vancomycin
19%
Study Participant
19%
Deprescribing
19%
Logistic Regression Analysis
14%
Thorax Pain
12%
Pilot Study
10%
Clinical Outcome
10%
Odds Ratio
10%
Public Health
9%
Health Care Personnel
9%
Cigarette Filter
6%
Dyspnea
6%
Exposure to Violence
6%
Safety Procedure
6%
Verbal Hostility
6%
Power Analysis
6%
Medicine and Dentistry
Parasympatholytic
40%
Cross Sectional Study
28%
Booster Dose
19%
Non Prescription Drug
19%
Randomized Clinical Trials
19%
Therapeutic Drug Monitoring
19%
Vancomycin
19%
Health Belief Model
19%
COVID-19
19%
FDA Adverse Event Reporting System
19%
University Student
19%
Multiple Myeloma
19%
Adverse Event
12%
Medication Compliance
9%
Arm
9%
Ixazomib
5%
Primary Outcome
5%
